FDA Brief

Warning letters Drugs

FDA warning letter to

Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine

High riskIssued Nov 10, 2021Posted Nov 16, 2021Division of Pharmaceutical Quality Operations Division III

Advanced Nutriceuticals compounded sterile drugs without required prescriptions and under insanitary conditions, FDA says.

What happened

FDA inspected the facility from October 13 to October 29, 2020, and issued a Form FDA 483 (inspection findings list). Investigators found that some compounded drugs lacked valid patient-specific prescriptions and were made with bulk ingredients not eligible for the special compounded-drug exemptions under section 503A. They also documented serious sterile-processing deficiencies, including filling outside a controlled clean-air area, poor aseptic technique, no media fills (sterility practice tests), and no environmental monitoring since 2018; the firm later stopped sterile production and recalled all compounded sterile products within expiry.

What FDA found

  1. The firm did not receive valid prescriptions for individual patients for some compounded drugs, including Energy Boost.

    FDCA section 503A [21 U.S.C. § 353a]
  2. The firm used bulk ingredients that do not qualify for the compounded-drug exemptions under section 503A.

    FDCA section 503A(b)(1)(A)(i) [21 U.S.C. § 353a(b)(1)(A)(i)]
  3. The firm filled sterile drugs into syringes in an unclassified dispensary area, with personnel in street clothes and no gloves, outside a certified clean-air area.

    FDCA section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  4. The firm showed poor aseptic technique and wore non-sterile gloves, street clothes, and exposed skin in the clean-air area, and personnel had never done media fills (sterility practice tests).

    21 CFR 211.113(b); 21 CFR 211.28(a)
  5. The firm had not monitored environmental conditions since 2018 and used an IV hood that had not been certified in over two years in an unclassified room.

    21 CFR 211.42(c)(10)(iv); 21 CFR 211.42(a)
  6. The firm had no FDA-approved applications for the ineligible compounded drugs and their labeling lacked adequate directions for use.

    FDCA sections 505(a) and 502(f)(1) [21 U.S.C. §§ 355(a), 352(f)(1)]

What FDA wants

FDA asks the firm to respond in writing within 15 working days describing corrective steps or stating it will not resume sterile production; if it plans to resume, FDA asks for documentation and notice 15 working days before restarting.

Who should pay attention

  • clinics and physicians that order compounded sterile drugs
  • patients receiving compounded sterile injections
  • buyers or suppliers of compounded products from this firm

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk